<DOC>
	<DOC>NCT02525094</DOC>
	<brief_summary>To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis</brief_summary>
	<brief_title>Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis</brief_title>
	<detailed_description>This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate to severe Atopic Dermatitis. Subjects will be randomized in a 1:1 fashion and will be stratified at screening. Approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>AD meeting Hanifin and Rajka criteria Age 1875 years inclusive at screening Atopic dermatitis that affects greater than/equal to 10% body surface area Moderate to severe AD Effective birth control in line with protocol details Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis Hepatitis B, C or HIV Pregnant or breastfeeding History of anaphylaxis following any biologic therapy History of clinically significant infections within 4 weeks prior to Visit 3 Diagnosis of helminth parasitic infection within 6 months to screening History of Cancer except basal cell Receipt of any marketed or investigational biologic agent within 4 months to visit 3 Any clinically relevant abnormal finding Major surgery within 8 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>